All dayManchester Airport
This study day is being organised by Amgen.
Elaine will deliver the morning session, covering:
The cellular and genetic make-up of acute lymphoblastic leukaemia (ALL)
• A bit about B cells
• Genetic drivers of ALL
• Clonal evolution & intratumoural heterogeneity
• The role of leukaemic stem cells
Treating Philadelphia Chromosome Positive ALL
• Bcr-Abl inhibitors
• Other treatments
Licensed and novel treatments for ALL
• Inotuzumab ozogamicin
• CAR-modified T cells
• Other treatments in trials
Contact Elaine if you would like to know how to book a place.
9:15 - 10:15Birmingham
Elaine will be delivering a plenary session on Sunday morning.
View the full programme:
Royal Marsden Hospital, London
Description: 1-day course covering a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. Treatments described include: growth factor receptor inhibitors, kinase inhibitors, monoclonal antibodies, PARP inhibitors, ALK inhibitors, CDK inhibitors, immunotherapies.
Audience: Ideal for pharmacists, research nurses, pharmaceutical companies, junior doctors or anyone who has been on one of Elaine’s other courses
To book, contact: firstname.lastname@example.org
View an outline of the programme